Not sure I agree with this logic. It seems a little too tea leaf’ish. Reminds me of the tote bag.
I don’t see a reason why Bosch can’t be an author as long as the proper disclosures are made. He is a contributor to the science and that is his capacity on the abstract.
Agree Crash and if it doesn’t unfold that way that’s ok for me since my plan is to realize gains next year…..12.31.23 will include JA, Uk approvals, a partnership, other RA approvals and solid indications on the combo trials. At that time my entire position will be long term cap gain.